ST諾泰(688076.SH):注射用醋酸西曲瑞克、阿戈美拉汀片獲得藥品註冊證書
格隆匯7月31日丨ST諾泰(688076.SH)公佈,近日收到國家藥品監督管理局核准簽發的注射用醋酸西曲瑞克、阿戈美拉汀片的《藥品註冊證書》,醋酸西曲瑞克作為第三代GnRH拮抗劑,在輔助生殖技術中相較於其他同類藥物(如GnRH激動劑或其他拮抗劑如加尼瑞克)具有獨特的臨牀優勢。醋酸西曲瑞克在起效速度、安全性(OHSS預防)、治療週期縮短和患者耐受性上顯著優於GnRH激動劑,且相較於其他拮抗劑(如加尼瑞克)注射反應更輕,是輔助生殖中高效、靈活的選擇。
阿戈美拉汀作為一種新型抗抑鬱藥,與SSRIs(如舍曲林、氟西汀)、SNRIs(如文拉法辛)、NaSSA(如米氮平)等常見抗抑鬱藥相比,具有獨特且創新的雙重作用機制,是唯一兼具快速改善睡眠且不影響日間功能的抗抑鬱藥。此外,阿戈美拉汀還有極低性功能障礙風險、對體重影響小、耐受性好、撤藥反應少等優勢,在抑鬱症伴失眠市場佔據着重要的地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.